US2013316343A1PendingUtilityA1

Delta3, fthma-070, tango85, tango77, spoil, neokine, tango129, and integrin alpha subunit protein and nucleic acid molecules and uses thereof

Assignee: MILLENIUM THE TAKEDA ONCOLOGY COMPANYPriority: Apr 4, 1997Filed: Apr 19, 2013Published: Nov 28, 2013
Est. expiryApr 4, 2017(expired)· nominal 20-yr term from priority
C07K 14/47A61K 38/00C07K 2319/00C12Q 1/6876C12Q 1/48
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 . An isolated nucleic acid molecule selected from the group consisting of: a) a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:3; b) a nucleic acid molecule comprising a fragment of at least 500 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2; and e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof, under stringent conditions. 
     
     
         14 . The isolated nucleic acid molecule of  claim 13 , which is selected from the group consisting of: a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; and b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2. 
     
     
         15 . The nucleic acid molecule of  claim 13  further comprising vector nucleic acid sequences. 
     
     
         16 . A host cell which contains the nucleic acid molecule of  claim 13 . 
     
     
         17 . An isolated polypeptide selected from the group consisting of: a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or a complement thereof; b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3; and c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2. 
     
     
         18 . The isolated polypeptide of  claim 17 , comprising the amino acid sequence of SEQ ID NO:2. 
     
     
         19 . The isolated polypeptide of  claim 17  further comprising heterologous amino acid sequences. 
     
     
         20 . A method for detecting the presence of a polypeptide of  claim 17  in a sample, comprising: contacting the sample with a compound which selectively binds to a polypeptide of  claim 17 ; and determining whether the compound binds to the polypeptide in the sample. 
     
     
         21 . The method of  claim 20 , wherein the compound which binds to the polypeptide is an antibody. 
     
     
         22 . A method for detecting the presence of a nucleic acid molecule of  claim 13  in a sample, comprising the steps of: contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample. 
     
     
         23 . The method of  claim 22 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe. 
     
     
         24 . A method for identifying a compound which binds to a polypeptide of  claim 17  comprising the steps of: contacting a polypeptide, or a cell expressing a polypeptide of  claim 17  with a test compound; and determining whether the polypeptide binds to the test compound. 
     
     
         25 . A method for identifying a compound which modulates the activity of a polypeptide of  claim 17 , comprising: contacting a polypeptide of  claim 17  with a test compound; and determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide. 
     
     
         26 . An isolated antibody, or portion thereof, that specifically binds to a polypeptide selected from the group consisting of: a) the polypeptide comprising the amino acid sequence of SEQ ID NO:2; b) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 3; and c) the polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 98348. 
     
     
         27 . The antibody, or portion thereof, of  claim 26 , wherein said antibody is selected from the group consisting of: i) a monoclonal antibody; ii) a polyclonal antibody; iii) a bispecific antibody; and iii) a chimeric antibody. 
     
     
         28 . The antibody, or portion thereof, of  claim 26 , wherein said portion is a F(ab) fragment or a F(ab′) 2  fragment. 
     
     
         29 . The antibody, or portion thereof, of  claim 26 , wherein said antibody binds to amino acid residues 18-529 of SEQ ID NO:2. 
     
     
         30 . The antibody, or portion thereof, of  claim 26 , wherein said antibody is detectably labeled. 
     
     
         31 . The antibody, or portion thereof, of  claim 30 , wherein the detectable label is selected from the group consisting of: a) an enzyme; b) a fluorescent material; c) a luminescent material; d) a bioluminescent material; and e) a radioactive material.

Join the waitlist — get patent alerts

Track US2013316343A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.